Pharmalot Ed Silverman STAT Plus: Supreme Court rules against Amgen in closely watched case over scope of patent claims
Politics Sarah Owermohle and Brittany Trang STAT Plus: New Biden science agency ARPA-H launches first program, targeting bone regrowth
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs
Biotech Damian Garde STAT Plus: In Belgium, a native son returns to resurrect the drugmaker Galapagos — and ‘to get the trust back’
Pharmalot Ed Silverman STAT Plus: FTC widens probe into pharmacy benefit managers to include group purchasing organizations
Politics Rachel Cohrs STAT Plus: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes
Business Alexa Gagosz — Boston Globe STAT Plus: CVS Health to close clinical trial unit two years after launch
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FTC suit over Amgen spotlights ‘bundling’ deals with insurers; FDA staff says Pfizer RSV vaccine is effective
Biotech Matthew Herper STAT Plus: PTC Therapeutics’s PKU drug succeeds in trial, but bigger hurdles for company are ahead
Biotech Jason Mast STAT Plus: A new startup looks to turn the workhorse of gene therapy against cancer
Health Tech Mario Aguilar STAT Plus: Biotech and pharma execs wrestle with the ‘nightmare’ of developing digital biomarkers
Pharmalot Ed Silverman STAT Plus: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FTC may sue to block Amgen deal for Horizon; Supreme Court declines Teva appeal on skinny labeling
Health Tech Mohana Ravindranath STAT Plus: General Catalyst, Andreessen Horowitz bet on large language models for health care
Biotech Jonathan Wosen STAT Plus: Boundless Bio tests a cancer drug targeting once-mysterious DNA loops
Health Isabella Cueto and Olivia Goldhill STAT Plus: Ketamine clinics’ bust serves as warning of business challenge facing psychedelic therapy
Exclusive Lev Facher STAT Plus: Biden drug czar to summon naloxone makers to White House to discuss pricing
Pharmalot Ed Silverman STAT Plus: U.S. Supreme Court declines bid by Teva to hear ‘skinny labeling’ case with implications for generic drug access
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year
Hospitals Bob Herman STAT Plus: Hospital-insurer tussle in Arizona puts care denials front and center
Biotech Jason Mast and Adam Feuerstein STAT Plus: FDA advisory panel narrowly recommends approval for Sarepta’s gene therapy for Duchenne
Pharmalot Ed Silverman STAT Plus: Pharmalittle: U.S. Senate committee passes PBM bills; Pfizer CEO predicts pharma will sue over Medicare price negotiations
Biotech Adam Feuerstein and Jason Mast STAT Plus: Tracking the FDA advisory panel on Sarepta’s gene therapy for Duchenne muscular dystrophy